Free Trial

IDEXX Laboratories (IDXX) Stock Forecast & Price Target

IDEXX Laboratories logo
$535.54 +1.23 (+0.23%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$535.86 +0.33 (+0.06%)
As of 08/1/2025 05:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IDEXX Laboratories - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
3
Buy
6

Based on 9 Wall Street analysts who have issued ratings for IDEXX Laboratories in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 9 analysts, 3 have given a hold rating, 5 have given a buy rating, and 1 has given a strong buy rating for IDXX.

Consensus Price Target

$557.88
4.17% Upside
According to the 9 analysts' twelve-month price targets for IDEXX Laboratories, the average price target is $557.88. The highest price target for IDXX is $625.00, while the lowest price target for IDXX is $510.00. The average price target represents a forecasted upside of 4.17% from the current price of $535.54.
Get the Latest News and Ratings for IDXX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for IDEXX Laboratories and its competitors.

Sign Up

IDXX Analyst Ratings Over Time

TypeCurrent Forecast
8/3/24 to 8/3/25
1 Month Ago
7/4/24 to 7/4/25
3 Months Ago
5/5/24 to 5/5/25
1 Year Ago
8/4/23 to 8/3/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
6 Buy rating(s)
5 Buy rating(s)
7 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$557.88$558.11$524.75$582.88
Forecasted Upside4.17% Upside2.16% Upside10.46% Upside24.38% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

IDXX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

IDXX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

IDEXX Laboratories Stock vs. The Competition

TypeIDEXX LaboratoriesMedical CompaniesS&P 500
Consensus Rating Score
2.78
2.81
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside4.17% Upside10,407.36% Upside14.55% Upside
News Sentiment Rating
Positive News

See Recent IDXX News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/17/2025Leerink Partners
1 of 5 stars
Daniel Clark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$580.00 ➝ $600.00+15.47%
7/2/2025Stifel Nicolaus
4 of 5 stars
Jonathan Block
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetHold ➝ Hold$510.00 ➝ $540.00-0.44%
7/1/2025Jefferies Financial Group
2 of 5 stars
 Initiated CoverageBuy$625.00+16.53%
5/5/2025Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Erin Wright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$548.00 ➝ $558.00+19.13%
2/10/2025Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
David Westenberg
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetNeutral ➝ Neutral$435.00 ➝ $510.00+10.01%
2/4/2025Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Balaji Prasad
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$481.00 ➝ $520.00+10.86%
2/4/2025Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Michael Ryskin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetNeutral ➝ Neutral$475.00 ➝ $535.00+14.06%
12/2/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Clark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
10/11/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$630.00 ➝ $575.00+20.64%
7/25/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Massaro
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$580.00+23.05%
4/9/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform
1/17/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$500.00 ➝ $650.00+25.68%
12/7/2023BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$602.00+15.42%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 05:36 PM ET.


Should I Buy IDEXX Laboratories Stock? IDXX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, August 2, 2025. Please send any questions or comments about these IDEXX Laboratories pros and cons to contact@marketbeat.com.

IDEXX Laboratories
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in IDEXX Laboratories, Inc.:

  • The current stock price is around $535, reflecting a strong market position and investor confidence in the company's growth potential.
  • IDEXX Laboratories, Inc. has seen significant increases in institutional investments, indicating strong confidence from major investors.
  • The company has a solid financial foundation, with a low debt-to-equity ratio, suggesting it is well-positioned to manage its liabilities effectively.
  • Recent performance metrics show a healthy current ratio, which indicates that IDEXX Laboratories, Inc. can cover its short-term obligations, enhancing its financial stability.
  • With a market capitalization exceeding $43 billion, IDEXX Laboratories, Inc. is a major player in its industry, which can provide investors with a sense of security and growth potential.

IDEXX Laboratories
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in IDEXX Laboratories, Inc. for these reasons:

  • The stock has a high price-to-earnings (P/E) ratio, which may indicate that it is overvalued compared to its earnings, potentially leading to a price correction.
  • Insider selling activity has been noted, with a director recently selling a significant number of shares, which could raise concerns about the company's future prospects.
  • Despite strong institutional support, the high concentration of ownership by institutional investors (over 87%) may lead to volatility if these investors decide to sell.
  • The stock's beta of 1.54 suggests that it is more volatile than the market, which could pose risks for investors looking for stability.
  • Recent trading volumes have fluctuated, which may indicate uncertainty in market sentiment regarding the stock's future performance.

IDXX Forecast - Frequently Asked Questions

According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for IDEXX Laboratories is $557.88, with a high forecast of $625.00 and a low forecast of $510.00.

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 3 hold ratings, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" IDXX shares.

According to analysts, IDEXX Laboratories's stock has a predicted upside of 4.17% based on their 12-month stock forecasts.

IDEXX Laboratories has been rated by research analysts at Jefferies Financial Group, Leerink Partners, Morgan Stanley, and Stifel Nicolaus in the past 90 days.

Analysts like IDEXX Laboratories less than other "medical" companies. The consensus rating score for IDEXX Laboratories is 2.78 while the average consensus rating score for "medical" companies is 2.81. Learn more on how IDXX compares to other companies.


This page (NASDAQ:IDXX) was last updated on 8/3/2025 by MarketBeat.com Staff
From Our Partners